The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial
Open accessAbstract
The only causative treatment for IgE-mediated allergies is allergen-specific immunotherapy. However, fewer than 5% of allergy patients receive immunotherapy because of its long duration and risk of allergic side effects. We aimed at enhancing s.c. immunotherapy by direct administration of allergen into s.c. lymph nodes. The objective was to evaluate safety and efficacy compared with conventional s.c. immunotherapy. In a monocentric open-label trial, 165 patients with grass pollen-induced rhinoconjunctivitis were randomized to receive either 54 s.c. injections with pollen extract over 3 years [cumulative allergen dose 4,031,540 standardized quality units (SQ-U)] or 3 intralymphatic injections over 2 months (cumulative allergen dose 3,000 SQ-U). Patients were evaluated after 4 months, 1 year, and 3 years by nasal provocation, skin prick testing, IgE measurements, and symptom scores. Three low-dose intralymphatic allergen administrations increased tolerance to nasal provocation with pollen already within 4 months ( P < 0.001). Tolerance was long lasting and equivalent to that achievable after standard s.c. immunotherapy ( P = 0.291 after 3 years). Intralymphatic immunotherapy ameliorated hay fever symptoms ( P < 0.001), reduced skin prick test reactivity ( P < 0.001), decreased specific serum IgE ( P < 0.001), caused fewer adverse events than s.c. immunotherapy ( P = 0.001), enhanced compliance ( P < 0.001), and was less painful than venous puncture ( P = 0.018). In conclusion, intralymphatic allergen administration enhanced safety and efficacy of immunotherapy and reduced treatment time from 3 years to 8 weeks.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The major advantages of this route of allergen application are the markedly reduced duration of immunotherapy treatment (both time spent and number of visits) and the much lower amount of allergen required to achieve results.”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1716]
In the citing paper
“Clinical trials have illustrated that a reduction in AR symptoms can be achieved with just 3 doses of injected allergen, with a dosage interval of 1 month1716-1720 (Table IX.D.6).”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1716]
In the citing paper
“In 2008, Senti et al.1716 compared ILIT to SCIT and not to placebo.”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1716]
In the citing paper
“Most trials1716,1718-1721 used commercially available grass pollen or birch pollen allergen extract as the antigen.”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1716]
In the citing paper
“Of the 6 trials published thus far, 5 have demonstrated clinical efficacy and safety.1716-1720”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1716]
Citations
Cites
Allergen immunotherapy: Therapeutic vaccines for allergic diseases A WHO position paper
Bousquet, J., Lockey, R., & Malling, H.-J. (1998) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(98)70271-4 · Cited by 1,581
Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy
Durham, S. R., Walker, S. M., Varga, E.-M., Jacobson, M. R., O'Brien, F., Noble, W., Till, S. J., Hamid, Q. A., & Nouri-Aria, K. T. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410702 · Cited by 1,373
Möller, C., Dreborg, S., Ferdousi, H. A., Halken, S., Høst, A., Jacobsen, L., Koivikko, A., Koller, D. Y., Niggemann, B., Norberg, L. A., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.121317 · Cited by 1,065
Position Paper: Allergen standardization and skin tests
Dreborg, S., & Frew, A. (1993) · Allergy · doi:10.1111/j.1398-9995.1993.tb04756.x · Cited by 753
Allergen Immunotherapy: Therapeutic Vaccines for Allergic Diseases
Bousquet, J., Lockey, R., Malling, H. J., Alvarez-Cuesta, E., Canonica, G. W., Chapman, M. D., Creticos, P. J., Dayer, J. M., Durham, S. R., Demoly, P., et al. (1998) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)63136-5 · Cited by 736
Arbes Jr., S. J., Gergen, P. J., Elliott, L., & Zeldin, D. C. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.05.017 · Cited by 639 · cited 1×
“I allergies, such as allergic rhinoconjunctivitis and asthma, have become highly prevalent, affecting up to 35% of the population in westernized countries (1).”
BackgroundPajno, G. B., Barberio, G., De Luca, F., Morabito, L., & Parmiani, S. (2001) · Clinical & Experimental Allergy · doi:10.1046/j.1365-2222.2001.01161.x · Cited by 546
Varney, V. A., Gaga, M., Frew, A. J., Aber, V. R., Kay, A. B., & Durham, S. R. (1991) · BMJ · doi:10.1136/bmj.302.6771.265 · Cited by 384
Fibroblasts as Efficient Antigen-Presenting Cells in Lymphoid Organs
Kündig, T. M., Bachmann, M. F., DiPaolo, C., Simard, J. J. L., Battegay, M., Lother, H., Gessner, A., Kühlcke, K., Ohashi, P. S., Hengartner, H., et al. (1995) · Science · doi:10.1126/science.7761853 · Cited by 301
Self-citation(1993) · PubMed · Cited by 223
Research works printed but not linked: 1
- Epidemiology Surveys and Danske Equities (ALK-Abelló, Hørsholm, Denmark, 2005).
Cited by
Allergen immunotherapy: A practice parameter third update
Cox, L., Nelson, H., Lockey, R., Calabria, C., Chacko, T., Finegold, I., Nelson, M., Weber, R., Bernstein, D. I., Blessing-Moore, J., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.09.034 · Cited by 1,256
From Sewer to Saviour—Targeting the Lymphatic System to Promote Drug Exposure and Activity
Trevaskis, N. L., Kaminskas, L. M., & Porter, C. J. H. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4608 · Cited by 654
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers
Shamji, M. H., & Durham, S. R. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.10.010 · Cited by 446
Metadata
- Authors
- Senti, G., Prinz Vavricka, B. M., Erdmann, I., Diaz, M. I., Markus, R., McCormack, S. J., Simard, J. J., Wüthrich, B., Crameri, R., Graf, N., Johansen, P., & Kündig, T. M.
- Affiliations
- University Hospital Zurich (CH)
- Unit for Experimental Immunotherapy, Department of Dermatology, and
- MannKind Corporation (United States) (US)
- Swiss Institute for Asthma and Allergy Research, 7270 Davos, Switzerland
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-11-18
- Volume
- 105
- Issue
- 46
- Pages
- 17908-17912
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2582048
- OpenAlex
- W1975755712
- Cited by
- 364
- References
- 26
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 14 · 2023: 22 · 2022: 26 · 2021: 18 · 2020: 21 · 2019: 12 · 2018: 18 · 2017: 23 · 2016: 24 · 2015: 19 · 2014: 35 · 2013: 30 · 2012: 26
- FWCI
- 12.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (114634, 310000)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- allergen immunotherapy, subcutaneous immunotherapy, grass pollen allergy, rhinoconjunctivitis, allergic rhinitis, IgE-mediated allergy, lymph node injection, treatment duration, treatment safety, medication adherence
- MeSH terms
- Adolescent, Adult, Aged, Allergens, Desensitization, Immunologic, Female, Humans, Hypersensitivity, Immunoglobulin E, Immune Tolerance, Injections, Intralymphatic, Injections, Subcutaneous, Male, Middle Aged, Pain, Skin Tests, Time Factors, Treatment Outcome, Anti-Allergic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial. https://app.cochat.ai/papers/10.1073/pnas.0803725105
- The paper
- Senti, G., Prinz Vavricka, B. M., Erdmann, I., Diaz, M. I., Markus, R., McCormack, S. J., Simard, J. J., Wüthrich, B., Crameri, R., Graf, N., Johansen, P., & Kündig, T. M. (2008). Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0803725105
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.